ABOUT US
About
Company Culture
Executive Team
Advisory Board
Contact
SCIENCE
Technical Platforms
Presentations and Publications
PIPELINE
PARTNERING
NEWS
JOIN US
Our Culture
Benefits
Opportunities
中文
Home
Close
ABOUT US
About
Company Culture
Executive Team
Advisory Board
Contact
SCIENCE
Technical Platform
Presentations and Publications
PIPELINE
Pipeline
PARTERING
Partnering
NEWS
News
CAREERS
Cultures
Benefit
Opportunities
Assets in clinical
development
5
Innovative therapies in
preclinical or clinical
development
10+
Partnered programs
8
RICH PIPELINE OF
BREAKTHROUGH THERAPEUTICS
Download Overview
Molecule:
BSI-045B
Modality / Target:
mAb, TSLP
Severe Asthma
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Atopic Dermatitis
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
COPD
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
ANKEBIO - China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Auto-Immune
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
OBI - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
Celldex - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
PYXIS - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Molecule:
BSI-502
Modality / Target:
bsAb, targets undisclosed
Severe Asthma
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Atopic Dermatitis
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
COPD
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
ANKEBIO - China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Auto-Immune
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
OBI - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
Celldex - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
PYXIS - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Molecule:
BSI-038
Modality / Target:
mAb, CD40
Severe Asthma
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Atopic Dermatitis
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
COPD
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
ANKEBIO - China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Auto-Immune
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
OBI - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
Celldex - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
PYXIS - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Molecule:
BSI-060T
Modality / Target:
mAb, Siglec-15
Severe Asthma
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Atopic Dermatitis
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
COPD
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
ANKEBIO - China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Auto-Immune
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
OBI - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
Celldex - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
PYXIS - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Molecule:
BSI-585
Modality / Target:
bsAb, PD1/ILT4
Severe Asthma
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Atopic Dermatitis
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
COPD
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
ANKEBIO - China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Auto-Immune
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
OBI - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
Celldex - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
PYXIS - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Molecule:
BSI-04702
Modality / Target:
ADC, TROP2
Severe Asthma
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Atopic Dermatitis
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
COPD
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
ANKEBIO - China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Auto-Immune
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
OBI - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
Celldex - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
PYXIS - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Molecule:
BSI-082
Modality / Target:
mAb, SIRPα
Severe Asthma
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Atopic Dermatitis
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
COPD
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
ANKEBIO - China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Auto-Immune
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
OBI - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
Celldex - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
PYXIS - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Molecule:
BSI-001
Modality / Target:
mAb, HER2
Severe Asthma
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Atopic Dermatitis
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
COPD
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
ANKEBIO - China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Auto-Immune
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
OBI - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
Celldex - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
PYXIS - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Molecule:
BSI-075
Modality / Target:
mAb, PVRIG
Severe Asthma
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Atopic Dermatitis
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
COPD
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
ANKEBIO - China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Auto-Immune
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
OBI - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
Celldex - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
PYXIS - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Molecule:
BSI-500
Modality / Target:
bsAb, targets undisclosed
Severe Asthma
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Atopic Dermatitis
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
COPD
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
ANKEBIO - China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Auto-Immune
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
OBI - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
Celldex - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
PYXIS - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Molecule:
BSI-729
Modality / Target:
bsAb, targets undisclosed
Severe Asthma
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Atopic Dermatitis
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
COPD
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
ANKEBIO - China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Auto-Immune
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
OBI - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
Celldex - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
PYXIS - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Molecule:
BSI-712
Modality / Target:
ADC, LIV-1
Severe Asthma
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Atopic Dermatitis
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
COPD
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
ANKEBIO - China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Auto-Immune
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
OBI - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
Celldex - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
PYXIS - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Molecule:
BSI-709
Modality / Target:
ADC, CDH6
Severe Asthma
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Atopic Dermatitis
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
COPD
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
ANKEBIO - China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Auto-Immune
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
OBI - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
Celldex - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
PYXIS - Ex China
Preclinical
Phase I
Phase II
Phase III
Solid Tumors
Partner:
CTTQ - China
Preclinical
Phase I
Phase II
Phase III
Copyright © 2022. Biosion All rights reserved.
苏ICP备2022027163号
Copyright © 2022. Biosion All rights reserved.
苏ICP备2022027163号
ABOUT US
About
Company Culture
Executive Team
Advisory Board
Contact
SCIENCE
Technical Platforms
Presentations and Publications
PIPELINE
PARTNERING
NEWS
JOIN US
Our Culture
Benefits
Opportunities
中文
Home
Close
ABOUT US
About
Company Culture
Executive Team
Advisory Board
Contact
SCIENCE
Technical Platform
Presentations and Publications
PIPELINE
Pipeline
PARTERING
Partnering
NEWS
News
CAREERS
Cultures
Benefit
Opportunities
PIPELINE
Assets in clinical
development
5
Innovative therapies in
preclinical or clinical
development
10+
Partnered programs
8
Filter by:
All categories
Immunology
Oncology
Download Overview
BSI-045B
Modality / Target:
mAb, TSLP
MORE
Severe Asthma
Preclinical
Phase I
Phase II
Phase III
Partner
CTTQ - China
Atopic Dermatitis
Preclinical
Phase I
Phase II
Phase III
COPD
Preclinical
Phase I
Phase II
Phase III
BSI-502
Modality / Target:
bsAb, targets undisclosed
MORE
Auto-Immune
Preclinical
Phase I
Phase II
Phase III
BSI-038
Modality / Target:
mAb, CD40
MORE
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Partner
CTTQ - China
BSI-060T
Modality / Target:
mAb, Siglec-15
MORE
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Partner
PYXIS - Ex China
BSI-585
Modality / Target:
bsAb, PD1/ILT4
MORE
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Partner
Celldex - Ex China
BSI-04702
Modality / Target:
ADC, TROP2
MORE
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Partner
OBI - Ex China
BSI-082
Modality / Target:
mAb, SIRPα
MORE
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
BSI-001
Modality / Target:
mAb, HER2
MORE
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Partner
ANKEBIO - China
BSI-075
Modality / Target:
mAb, PVRIG
MORE
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
BSI-500
Modality / Target:
bsAb, targets undisclosed
MORE
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Partner
CTTQ - China
BSI-729
Modality / Target:
bsAb, targets undisclosed
MORE
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
BSI-712
Modality / Target:
ADC, LIV-1
MORE
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
BSI-709
Modality / Target:
ADC, CDH6
MORE
Solid Tumors
Preclinical
Phase I
Phase II
Phase III
Copyright © 2022. Biosion All rights reserved.
苏ICP备2022027163号
Copyright © 2022. Biosion All rights reserved.
苏ICP备2022027163号